TG Therapeutics Inc

TG Therapeutics shares have risen 15.1% since its second-quarter earnings report, outperforming the S&P 500. The company reported earnings of 5 cents per share, missing the Zacks Consensus Estimate of 41 cents, but total revenues of $240.3 million beat estimates and rose 70.3% year over year, driven by strong sales of its drug Briumvi. Management raised its 2026 total revenue guidance to around $950 million from $925 million, and narrowed U.S. Briumvi net product sales guidance to $890-$905 million. However, estimates have trended downward over the past month, and the stock holds a Zacks Rank #3 (Hold).

TG Therapeutics shares rose after its key multiple sclerosis drug Briumvi posted greater than anticipated growth and positive clinical data emerged for a subcutaneous version that could expand its addressable market. The commercial-stage biopharmaceutical company was highlighted as a leading contributor in ClearBridge Investments' SMID Cap Growth Strategy second-quarter 2026 commentary. The strategy noted biotechnology was a bright spot, with multiple holdings delivering strong performance. TG Therapeutics closed at $57.12 per share on July 10, 2026, with a market capitalization of $8.74 billion, and its shares gained 46.76% over the past 52 weeks.

Incyte and TG Therapeutics are two fast-growing pharmaceutical stocks attracting investor attention. Incyte reported first-quarter revenue of $1.27 billion, up 21% year over year, driven by Jakafi sales of $758 million and Opzelura sales of $143 million, with adjusted earnings per share of $1.81 beating analyst estimates. The company anticipates four new approvals and launches through early 2027, supported by a pipeline that includes a recent $1.25 billion acquisition of Vega Therapeutics. TG Therapeutics raised its full-year revenue guidance to $925 million after Briumvi generated $194.8 million in first-quarter U.S. sales, and its strong gross margins and growth make it a potential acquisition target for large pharmaceutical companies.

TG Therapeutics has initiated a Phase 2 clinical trial evaluating BRIUMVI in adults with treatment-resistant schizophrenia. The open-label, single-arm, multicenter study will enroll approximately 60 participants aged 18 to 60 who continue to experience significant symptoms despite standard-of-care antipsychotic treatment. The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12. BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody already approved for relapsing forms of multiple sclerosis, and this trial explores its potential in addressing immune dysfunction and neuroinflammation linked to schizophrenia.

TG Therapeutics' multiple sclerosis drug Briumvi generated $201.3 million in total sales in the first quarter of 2026, a 68.2% year-over-year increase, with U.S. net product sales of $194.8 million rising 63%. The company expects U.S. net sales of Briumvi to reach $220 million in the second quarter of 2026, driven by sustained demand. Briumvi, an anti-CD20 monoclonal antibody approved for relapsing forms of MS, faces competition from Roche's Ocrevus and Novartis' Kesimpta, both of which also reported sales growth in the last quarter. TG Therapeutics is conducting label expansion studies for Briumvi in other autoimmune diseases, which could broaden its patient reach and support long-term revenue growth. The company's stock has rallied 78.9% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has risen to $1.50 over the past 60 days.